LAG3 and COVID-19: More recently, based on studies showing a transient increase in the expression of this receptor during immune activation as part of COVID-19, the use of LAG-3 blockers (alone or in combination with other checkpoint inhibitors) during the early or late phase of SARS-CoV-2 infection has been proposed as an effective therapeutic measure for treatment [9,97].